Answers are grounded in this paper and cite their sources.
Background: In prostate carcinoma, there is controversy about optimal use of hormonal therapy with external beam radiotherapy: who will benefit, for how long, neo-adjuvant versus concurrent versus adjuvant.
No takes yet. Share an insight, caveat, or question.
Mahmoud et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: